Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2021-003799-15
    Sponsor's Protocol Code Number:ACE1100-01
    National Competent Authority:Spain - AEMPS
    Clinical Trial Type:EEA CTA
    Trial Status:Ongoing
    Date on which this record was first entered in the EudraCT database:2022-02-18
    Trial results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedSpain - AEMPS
    A.2EudraCT number2021-003799-15
    A.3Full title of the trial
    A Randomized, Double-blind Study to Investigate the Safety, Pharmacokinetics, and Antitumor Activity of ASC-201 Plus Trifluridine/Tipiracil Compared With Trifluridine/Tipiracil in Patients With Advanced Gastric Cancer in a Third Line Treatment Setting After an Initial Dose Escalation Phase
    Estudio aleatorizado, doble ciego, para investigar la seguridad, la farmacocinética y la actividad antitumoral de ASC-201 más trifluridina/tipiracilo en comparación con trifluridina/tipiracilo en pacientes con cáncer gástrico avanzado en un contexto de tratamiento de tercera línea tras una fase de aumento escalonado de la dosis inicial
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    ASC-201 Plus Trifluridine/Tipiracil for the Treatment of Advanced Gastric Cancer
    ASC-201 más trifluridina/tipiracilo para el tratamiento del cáncer gástrico avanzado
    A.4.1Sponsor's protocol code numberACE1100-01
    A.5.4Other Identifiers
    Name:INDNumber:157164
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorAscelia Pharma AB
    B.1.3.4CountrySweden
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportAscelia Pharma AB
    B.4.2CountrySweden
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationAscelia Pharma AB
    B.5.2Functional name of contact pointMarie Källström
    B.5.3 Address:
    B.5.3.1Street AddressHyllie Boulevard 34
    B.5.3.2Town/ cityMalmö
    B.5.3.3Post code215 32
    B.5.3.4CountrySweden
    B.5.4Telephone number+4673517 91 20
    B.5.6E-mailmk@ascelia.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameASC-201
    D.3.4Pharmaceutical form Gastro-resistant tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNIRINOTECAN
    D.3.9.1CAS number 97682-44-5
    D.3.9.2Current sponsor codeSPT1370
    D.3.9.3Other descriptive name(+)-Irinotecan
    D.3.9.4EV Substance CodeSUB08295MIG
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number7.5 and 10
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 2
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name Lonsurf
    D.2.1.1.2Name of the Marketing Authorisation holderLes Laboratoires Servier
    D.2.1.2Country which granted the Marketing AuthorisationEuropean Union
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameTrifluridine/Tipiracil
    D.3.4Pharmaceutical form Film-coated tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNTrifluridine/Tipiracil
    D.3.9.1CAS number 733030-01-8
    D.3.9.2Current sponsor codeTAS-102
    D.3.9.3Other descriptive nameTIPIRACIL HYDROCHLORIDE MIXTURE WITH TRIFLURIDINE
    D.3.9.4EV Substance CodeSUB78359
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typerange
    D.3.10.3Concentration number15 to 20
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNTrifluridine/Tipiracil
    D.3.9.1CAS number 733030-01-8
    D.3.9.2Current sponsor codeTAS-102
    D.3.9.3Other descriptive nameTIPIRACIL HYDROCHLORIDE MIXTURE WITH TRIFLURIDINE
    D.3.9.4EV Substance CodeSUB78359
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typerange
    D.3.10.3Concentration number6.14 to 8.19
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    D.8 Placebo: 1
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboGastro-resistant tablet
    D.8.4Route of administration of the placeboOral use
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Advanced Gastric Cancer.
    Cáncer gástrico avanzado.
    E.1.1.1Medical condition in easily understood language
    Advanced Gastric Cancer.
    Cáncer gástrico avanzado.
    E.1.1.2Therapeutic area Diseases [C] - Digestive System Diseases [C06]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.0
    E.1.2Level SOC
    E.1.2Classification code 10017947
    E.1.2Term Gastrointestinal disorders
    E.1.2System Organ Class 10017947 - Gastrointestinal disorders
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    Phase 1:
    To assess the safety and tolerability of ASC-201 plus trifluridine/tipiracil when dosed concomitantly in patients with advanced gastric or gastroesophageal junction cancer. To determine the recommended Phase 2 dose (RP2D) and/or maximum tolerated dose (MTD) of the combination.
    Phase 2:
    To evaluate the efficacy of ASC-201 plus trifluridine/tipiracil relative to placebo plus trifluridine/tipiracil by assessment of PFS in patients with advanced or metastatic gastric cancer.
    Fase I:
    Evaluar la seguridad y la tolerabilidad de ASC-201 junto con trifluridina/tipiracilo cuando se administra de forma concomitante en pacientes con cáncer gástrico o de la unión gastroesofágica avanzado.
    Determinar la dosis recomendada de la fase II (DRF2) o la dosis máxima tolerada (DMT) de la combinación.
    Fase II:
    Evaluar la eficacia de ASC-201 más trifluridina/tipiracilo con respecto a placebo más trifluridina/tipiracilo mediante la evaluación de la SSP en pacientes con cáncer gástrico avanzado o metastásico.
    E.2.2Secondary objectives of the trial
    Phase 1:
    To estimate the efficacy of ASC-201 plus trifluridine/tipiracil when dosed concomitantly by assessment of objective response rate (ORR), duration of response (DoR) for patients with measurable disease, and progression free survival (PFS) in all patients.
    Phase 2:
    To evaluate the efficacy of ASC-201 plus trifluridine/tipiracil relative to placebo plus trifluridine/tipiracil by assessment of overall survival (OS) in patients with advanced or metastatic gastric cancer.
    Fase I:
    Estimar la eficacia de ASC-201 más trifluridina/tipiracilo cuando se administra de forma concomitante mediante la evaluación de la tasa de respuesta objetiva (TRO), la duración de la respuesta (DR) para los pacientes con enfermedad medible y la supervivencia sin progresión (SSP) en todos los pacientes
    Fase II:
    Evaluar la eficacia de ASC-201 más trifluridina/tipiracilo en comparación con placebo más trifluridina/tipiracilo mediante la evaluación de la supervivencia general (SG) en pacientes con cáncer gástrico avanzado o metastásico.
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    Patients are eligible to be included in the study only if all of the following criteria apply:
    1. Capable of giving signed informed consent as described in Appendix 2 which includes compliance with the requirements and restrictions listed in the ICF and in this protocol.
    2. Male or female patients must be ≥18 years of age, at the time of signing the informed consent.
    3. Patients with histologically or cytologically confirmed gastric cancer or gastroesophageal junction adenocarcinoma.
    4. Are candidates for trifluridine/tipiracil therapy, having metastatic gastric gastroesophageal junction adenocarcinoma, who have been previously treated with at least two prior systemic treatment regimens for advanced disease.
    5. Has measurable disease based on RECIST v.1.1 as determined by the site study team.

    Please see protocol v2.0 for full inclusion criteria.
    Los pacientes sólo son elegibles para ser incluidos en el estudio si se aplican todos los criterios siguientes:
    1. Capaces de dar consentimiento informado firmado, tal y como se describe en el Apéndice 2, que incluye los requisitos y las restricciones enumerados en el ICF y en este protocolo.
    2. Los hombres y mujeres deben tener ≥18 años de edad, en el momento de firmar el consentimiento informado.
    3. Pacientes con cáncer gástrico o adenocarcinoma de la unión gastroesofágica confirmado histológica o citológicamente.
    4. Son candidatos a la terapia con trifluridina/tipiracilo con adenocarcinoma gástrico de la unión gastroesofágica metastásico, que hayan sido tratados previamente con al menos dos pautas previas de tratamiento sistémico en la enfermedad avanzada.
    5. Tener una enfermedad medible según la norma RECIST v.1.1, según lo determine el equipo de estudio del centro.

    Consulte el protocolo v2.0 para ver los criterios de inclusión completos.
    E.4Principal exclusion criteria
    Patients are excluded from the study if any of the following criteria apply:
    1. History of previous malignancy other than gastric cancer within the last 2 years except basal cell carcinoma or carcinoma in situ in solid organ.
    2. Presence of chronic inflammatory bowel disease and/or bowel obstruction.
    3. Homozygous for the uridine diphosphate glucuronosyltransferase (UGT1A1) *28 allele (Gilbert's syndrome) or otherwise known to have reduced UGT1A1 activity (applies for Phase 1 only).
    4. Known central nervous system or brain metastases, unless previously treated and stable for 3 months.
    5. Poorly controlled ascites and/or requirement for therapeutic paracentesis more frequently than once every 3 months.
    6. Any other ongoing significant disease, or condition other than gastric cancer as judged by the Investigator to compromise the patients' ability to complete this study, eg but not limited to an active infection (including active hepatitis B, hepatitis C or HIV infections), unresolved pneumonia/pneumonitis, uncontrolled diabetes, poorly controlled hypertension or other cardiovascular disease.
    7. Previously received irinotecan treatment for gastric cancer.
    8. Receiving concomitant medication that are:
    (a) Strong inhibitors (eg, ketoconazole) of CYP3A4, OR
    (b) Strong inducers (eg, rifampicin, carbamazepine, phenobarbital, phenytoin, St John's wort) of CYP3A4, OR
    (c) Substrates of human thymidine kinase (eg, zidovudine).
    9. Receiving any other investigational agent within 4 weeks prior to Screening.
    10. Enrolled in another clinical study with an IMP.

    Please see protocol v2.0 for full exclusion criteria.
    Los pacientes son excluidos del estudio si alguno de los siguientes criterios aplica:
    1. Antecedentes de neoplasias previas distintas del cáncer gástrico en los últimos 2 años, excepto carcinoma de células basales o carcinoma in situ en órgano sólido.
    2. Presencia de enfermedad inflamatoria intestinal crónica y/o obstrucción intestinal.
    3. Homocigoto para la uridina difosfato glucuronosiltransferasa (UGT1A1) *alelo 28 (síndrome de Gilbert) o se sabe que tiene una actividad reducida de la UGT1A1 (se aplica sólo a la fase 1).
    4. Metástasis conocidas en el sistema nervioso central o en el cerebro, a menos que hayan sido tratadas previamente y estén estables durante 3 meses.
    5. Ascitis mal controlada y/o necesidad de paracentesis terapéutica más de una vez cada 3 meses.
    6. Cualquier otra enfermedad o afección significativa en curso, distinta del cáncer gástrico, que a juicio del investigador pueda comprometer la capacidad del paciente para completar este estudio, por ejemplo, pero sin limitarse a una infección activa (incluidas las infecciones activas por hepatitis B, hepatitis C o VIH), neumonía/neumonitis no resuelta, diabetes no controlada, hipertensión mal controlada u otra enfermedad cardiovascular.
    7. Haber recibido previamente tratamiento con irinotecán para el cáncer gástrico.
    8. Recibir medicación concomitante que sea
    (a) Inhibidores fuertes del CYP3A4 (por ejemplo, ketoconazol), o
    (b) Inductores fuertes del CYP3A4 (p. ej., rifampicina, carbamazepina, fenobarbital, fenitoína, hierba de San Juan), o
    (c) Sustratos de la timidina quinasa humana (p. ej., zidovudina).
    9. Recibir cualquier otro producto en investigación en las 4 semanas anteriores al cribado.
    10. Estar inscrito en otro estudio clínico con un PEI.

    Consulte los criterios de exclusión completos en el protocolo v2.0.
    E.5 End points
    E.5.1Primary end point(s)
    Phase 1:
    Safety and tolerability will be evaluated in terms of dose limiting toxicities (DLTs), adverse events (AEs)/serious AEs (SAEs), vital signs, clinical chemistry/hematology parameters, and electrocardiogram (ECG) parameters. The measures of interest are patient incidence rates, absolute values, and change from baseline over time (AEs will be categorized by intensity using Common Terminology Criteria for Adverse Events Version 5.0 [CTCAE v5.0]).

    Phase 2:
    Progression free survival is defined as the time from randomization until progression per RECIST v.1.1 as assessed by the Investigator or death due to any cause. The comparison will include all randomized patients, as randomized, regardless of whether the patient withdraws from randomized therapy, receives another anti-cancer therapy, or clinically progresses prior to RECIST v.1.1 progression. However, if the patient progresses or dies immediately after 2 or more consecutive missed visits, the patient will be censored at the time of the latest evaluable assessment prior to the 2 missed visits. The measure of interest is the hazard ratio (HR) of PFS.
    Fase I:
    La seguridad y la tolerabilidad se evaluarán en términos de toxicidades limitantes de la dosis (TLD), acontecimientos adversos (AA)/AA graves (AAG), constantes vitales, parámetros de bioquímica clínica/hematología y parámetros de electrocardiograma (ECG).
    Las medidas de interés son las tasas de incidencia de los pacientes, los valores absolutos y el cambio desde el inicio a lo largo del tiempo (los AA se categorizarán por intensidad utilizando los criterios terminológicos comunes para acontecimientos adversos, versión 5.0 [CTCAE v5.0]).
    Fase II:
    La supervivencia sin progresión se define como el tiempo transcurrido desde la aleatorización hasta la progresión según los criterios RECIST, v.1.1, según los criterios RECIST, v.1.1, evaluada por el investigador o la muerte por cualquier causa. La comparación incluirá a todos los pacientes aleatorizados, tal y como fueron aleatorizados, independientemente de que el paciente se retire del tratamiento aleatorizado, reciba otro tratamiento antineoplásico o progrese clínicamente antes de la progresión según los criterios RECIST, v.1.1. Sin embargo, si el paciente progresa o fallece inmediatamente después de 2 o más visitas consecutivas no realizadas, se censurará al paciente en el momento del último examen evaluable anterior a las 2 visitas no realizadas.
    La medida de interés es el cociente de riesgos (CR) de la SSP.
    E.5.1.1Timepoint(s) of evaluation of this end point
    Phase 1:
    Safety endpoints include DLTs, AEs and SAEs, laboratory data, vital signs, and ECG changes.
    Descriptive statistics will be used primarily to summarize the safety data in Phase 1.
    Other safety data including physical examinations, clinical hematology, chemistry, urinalysis, vital signs and ECGs will be summarized using descriptive statistics. The analysis will be performed based on the FAS.
    The RP2D will be determined based on an assessment of PK, safety, and efficacy data and may take account of data from other studies.

    Phase 2:
    Efficacy analyses will be based on the FAS Intent-to-Treat (ITT) (overall population).
    Fase I:
    Los criterios de seguridad incluyen TLD, AA y AAG, datos de laboratorio, constantes vitales y cambios en el ECG.
    La estadística descriptiva se usará principalmente para resumir los datos de seguridad en la fase 1.
    Otros datos de seguridad, incluidos los exámenes físicos, la hematología clínica, la química, el análisis de orina, los signos vitales y ECG, se resumirán utilizando estadísticas descriptivas. El análisis se realizará en base al FAS.
    La RP2D se determinará en base a una evaluación de los datos de PK, seguridad y eficacia y puede tener en cuenta los datos de otros estudios.
    Fase 2:
    Los análisis de eficacia se basarán en el principio de intención de tratar [ITT].
    E.5.2Secondary end point(s)
    Phase 1:
    Objective response rate is defined as the proportion of patients with measurable disease at baseline who have a confirmed complete response (CR) or confirmed partial response (PR), as determined by the Investigator at the local site per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v.1.1).

    Phase 2:
    Overall survival is defined as the time from randomization until the date of death due to any cause. The comparison will include all randomized patients, as randomized, regardless of whether the patient withdraws from therapy or receives another anti-cancer therapy.
    Objective response rate is defined as the proportion of patients who have a CR or PR, as determined by the Investigator at the local site per RECIST v.1.1.
    Safety and tolerability will be evaluated in terms of AEs/SAEs, vital signs, clinical chemistry/ hematology, and ECG parameters.
    Fase 1:
    La tasa de respuesta objetiva se define como la proporción de pacientes con enfermedad medible al inicio del estudio que presentan una respuesta completa (RC) confirmada o una respuesta parcial (RP) confirmada, determinada por el investigador en el centro local según los Criterios de Evaluación de la Respuesta en Tumores Sólidos, versión 1.I (RECIST v.1.1).
    Fase 2:
    La supervivencia general se define como el tiempo transcurrido desde la aleatorización hasta la fecha de muerte por cualquier causa. La comparación incluirá a todos los pacientes aleatorizados, tal y como fueron aleatorizados, independientemente de que el paciente abandone el tratamiento o reciba otro tratamiento antineoplásico.
    La tasa de respuesta objetiva se define como la proporción de pacientes con RC o RP, según los criterios RECIST, v.1.1, evaluada por el investigador en el centro local.
    La seguridad y la tolerabilidad se evaluarán en términos de AA/AAG, constantes vitales, bioquímica clínica/hematología y parámetros de ECG.
    E.5.2.1Timepoint(s) of evaluation of this end point
    Overall Survival is defined as time from randomization until the date of death due to any cause. The comparison will include all randomized patients, as randomized, regardless of whether the patient withdraws from therapy or receives another anti-cancer therapy.
    La supervivencia general se define como el tiempo transcurrido desde la aleatorización hasta la fecha de muerte por cualquier causa. La comparación incluirá a todos los pacientes aleatorizados, tal y como fueron aleatorizados, independientemente de que el paciente abandone el tratamiento o reciba otro tratamiento antineoplásico.
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy No
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic Yes
    E.6.7Pharmacodynamic Yes
    E.6.8Bioequivalence No
    E.6.9Dose response Yes
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) Yes
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other Yes
    E.7.1.3.1Other trial type description
    Phase 1/Phase 2
    E.7.2Therapeutic exploratory (Phase II) Yes
    E.7.3Therapeutic confirmatory (Phase III) No
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open Yes
    E.8.1.3Single blind No
    E.8.1.4Double blind No
    E.8.1.5Parallel group No
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) Yes
    E.8.2.2Placebo Yes
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial2
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned5
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA20
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Belgium
    France
    Italy
    Russian Federation
    Spain
    United Kingdom
    United States
    E.8.7Trial has a data monitoring committee Yes
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    Last Visit Last Patient.
    Última visita del último paciente
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years3
    E.8.9.1In the Member State concerned months0
    E.8.9.1In the Member State concerned days0
    E.8.9.2In all countries concerned by the trial years2
    E.8.9.2In all countries concerned by the trial months2
    E.8.9.2In all countries concerned by the trial days0
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 69
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 70
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state36
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 102
    F.4.2.2In the whole clinical trial 139
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    Phase 1:
    Patients who continue to derive clinical benefit from IMP in the opinion of the Investigator may continue to receive IMP until progression. IMPs will continue to be provided. Treatment beyond progression is not allowed.

    Phase 2:
    Patients who were randomized to receive placebo or who discontinue from the study, should continue appropriate treatment at the discretion of the Investigator. Such patients can continue to receive trifluridine/tipiracil if they are receiving benefit.
    Fase 1:
    Los pacientes que continúan obteniendo beneficio clínico del PEI en opinión del investigador podrán seguir recibiendo el PEI hasta la progresión. No se permite el tratamiento más allá de la progresión.
    Fase 2:
    Los pacientes que fueron aleatorizados para recibir placebo o que interrumpen el tratamiento, deben continuar con el tratamiento apropiado a discreción del investigador. Dichos pacientes pueden seguir recibiendo trifluridina/tipiracilo si obtienen beneficios.
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2022-04-25
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2022-03-28
    P. End of Trial
    P.End of Trial StatusOngoing
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue May 06 23:24:21 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA